Dibicor, tablets 500 mg 60 pcs

Indications

cardiovascular failure of various etiologies;
intoxication caused by cardiac glycosides;
type 1 diabetes mellitus;
diabetes mellitus type 2, incl. with moderate hypercholesterolemia;
as a hepatoprotector in patients taking antifungal drugs.

Pharmacological effect

Dibikor – metabolic.

Pharmacodynamics

Taurine is a natural metabolic product of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane protective properties, has a positive effect on the phospholipid composition of cell membranes, and normalizes the exchange of calcium and potassium ions in cells.

Taurine has been shown to have the properties of an inhibitory neurotransmitter; it has an anti-stress effect, can regulate the release of GABA, adrenaline, prolactin and other hormones, as well as regulate responses to them.

By participating in the synthesis of respiratory chain proteins in mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; affects enzymes such as cytochromes responsible for the metabolism of various xenobiotics.

Dibikor® improves metabolic processes in the heart, liver and other organs and tissues.

In chronic diffuse liver diseases, Dibikor® increases blood flow and reduces the severity of cytolysis. Treatment with Dibicor® for cardiovascular failure (CVF) leads to a reduction in congestion in the pulmonary and systemic circulation: intracardiac diastolic pressure decreases, myocardial contractility increases (maximum rate of contraction and relaxation, contractility and relaxation indices).

The drug moderately reduces blood pressure in patients with arterial hypertension and has virtually no effect on its level in patients with heart failure with low blood pressure.

Dibikor® reduces side effects that occur with an overdose of cardiac glycosides and blockers of “slow” calcium channels; reduces the hepatotoxicity of antifungal drugs. Increases performance during heavy physical activity.

In case of diabetes mellitus, approximately 2 weeks after starting to take Dibikor®, the blood sugar level decreases. There was also a significant decrease in the concentration of triglycerides, and to a lesser extent, cholesterol levels, and a decrease in the atherogenicity of plasma lipids. With long-term use of the drug (about 6 months), an improvement in the microcirculatory blood flow of the eye was noted.

Pharmacokinetics

After a single dose of 500 mg of Dibikor®, the active substance (taurine) is determined in the blood after 15–20 minutes, Cmax is reached after 1.5–2 hours. The drug is completely eliminated within 24 hours.

Special instructions

While taking Dibikor, the dose of cardiac glycosides should be reduced sometimes by 2 times, depending on the sensitivity of patients to cardiac glycosides.

The same rule applies to blockers of “slow” calcium channels.

Active ingredient

Taurine

Composition

Pills

Active ingredient:

taurine 500 mg;

Excipients:

MCC 46 mg;

potato starch 36 mg;

gelatin 12 mg;

colloidal silicon dioxide (Aerosil) 0.6 mg;

calcium stearate 5.4 mg;

Pack of 30 and 60 pcs.

Pregnancy

Data on the use of the drug during pregnancy and lactation are not provided.

Contraindications

Hypersensitivity to the drug; age under 18 years (efficacy and safety have not been established).

Side Effects

Allergic reactions to the components of the drug are possible.

Interaction

Dibikor® can be used with other drugs; enhances the inotropic effect of cardiac glycosides.

Overdose

There are no data on overdose.

Storage conditions

In a dry place, protected from light, at room temperature

Shelf life

3 years

Manufacturer

Pik-Pharma, Russia